Skip to main content

Roche and ETH training the next generation of researchers

| News

Roche and ETH training the next generation of researchers


Roche, the Basel-based life sciences firm, and the Swiss Federal Institute of Technology in Zurich (ETH) are joining forces to train biomedical researchers. At the ETH Zurich location in Basel, new drug development methods are also being researched.


Roche and the Swiss Federal Institute of Technology in Zurich (ETH) have agreed a research and training cooperation, further details of which can be found in a press release. This partnership will primarily be focused on the Department of Biosystems Science and Engineering (D-BSSE) of ETH Zurich, which is based in Basel. Moreover, the Basel-based life sciences firm’s new Institute of Human Biology (IHB) as well as its Pharma Research and Early Development department are located there too. “This kind of collaboration between academia and industry is unique”, as Vanessa Wood, Vice President Knowledge Transfer and Corporate Relations at ETH Zurich, explains in the press release.

Attract the best researchers

The cooperation is being implemented across two separate programs, one of which is focused on new methods of bioengineering and other on cellular and genetic model systems. A total of 20 doctoral students and 20 postdoctoral fellows, fully funded by Roche, will collaborate with researchers from Roche and ETH Zurich across a period of three to four years. “We are convinced that through our partnership and collaboration, we will attract and work with some of the best researchers in the world”, comments Hans Clevers, Head of Pharma Research and Early Development at Roche, in the press release. Through this joint work, Roche and ETH Zurich will therefore be training the next generation of biomedical researchers, who will become specialists to deal with future challenges.

In addition, the cooperation between Roche and ETH also provides a platform to research methods for the development of new drugs. For example, the researchers can work with organoids, 3D models of human organs. However, they will also gain experience in the area of machine learning algorithms for the evaluation of huge volumes of data. “Our new strong partnership with Roche empowers future leaders in bioengineering and translational medicine”, comments Professor Daniel Müller, who heads up the D-BSSE, in the press release.

Share this article

Sign up to receive our newsletter in your inbox.

You may also be interested in

biGENIUS receives 2 million euros for new cloud product

Software company biGENIUS, based in the Basel Area, has secured financing of 2 million euros. This funding was granted following...
Read More

Opterion Health secures investment of 6.5 million Swiss francs

Opterion Health has raised a total of 6.5 million Swiss francs as part of a financing round. The company, which...
Read More

TOLREMO receives 39 million US dollars in investments

TOLREMO Therapeutics has concluded a series A funding round with 39 million US dollars. The biotech company based in Basel...
Read More

Mazars opens tenth Swiss office in Basel

Mazars is now also present in Basel with a subsidiary as of September 1. This is the tenth Swiss location...
Read More

Medtech in Switzerland – bringing together traditional skills and hightech industry

How the intersection of traditional and novel skillsets in the Jura area is propelling Switzerland into a new era of...
Read More

Fondation Botnar supporting further research into pediatric health

The Basel-based Botnar Research Centre for Child Health has received a further donation of 50 million Swiss francs from the...
Read More

Do you have a question? We'd like to hear from you.